Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2014-01-23Clinical Trial Update: Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients [Phase 3]
A Phase 3 open-label trial comparing BI 207127 to telaprevir for chronic hepatitis C has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-11-25Clinical Trial Update: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients [Phase 3]
A Phase 3 trial evaluating pegylated interferon alfa + ribavirin + daclatasvir in treatment-naïve hepatitis C patients (genotypes 1 and 4) h…
-
CLINICAL_TRIALS withdrawal · 2013-11-19Clinical Trial Update: Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment [Phase 4]
The Phase 4 clinical trial evaluating preemptive treatment in orthotopic liver transplant recipients with hepatitis C has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-11-13Clinical Trial Update: Immune Response to Hepatitis C Virus
A clinical trial evaluating the immune response to hepatitis C virus sponsored by Emory University has been withdrawn from the registry.
-
CLINICAL_TRIALS withdrawal · 2013-07-22Clinical Trial Update: Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes [NA]
This University of Arizona clinical trial on inflammation, stress, and social behavior in Hepatitis C patients using ecological assessments …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2013-07-18Clinical Trial Update: Japanese Bridging Study Conducted in the United States [Phase 1]
Bristol-Myers Squibb’s Phase 1 bridging trial for a Hepatitis C virus therapy conducted in the United States has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-07-01Clinical Trial Update: A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C [Phase 2]
A Phase 2 pilot trial investigating the safety and efficacy of fluvastatin in genotype 1 hepatitis C patients who previously partially respo…
-
CLINICAL_TRIALS withdrawal · 2013-06-21Clinical Trial Update: Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients [Phase 1]
A Phase 1 multiple ascending dose study of BMS-929075 in patients with chronic hepatitis C has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-02-26Clinical Trial Update: A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection [Phase 3]
A Phase 3 trial of BI201335 for chronic hepatitis C in treatment-naive and relapsed patients has been withdrawn, with no results reported.
-
CLINICAL_TRIALS withdrawal · 2012-08-28Clinical Trial Update: Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy [Phase 1]
Phase 1 trial of TRAVELAN (hyperimmune bovine colostrum) for asymptomatic chronic hepatitis C carriers not responding to standard therapy ha…
-
CLINICAL_TRIALS withdrawal · 2012-04-25Clinical Trial Update: Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C [Phase 2]
A Phase 2 trial evaluating an angiotensin receptor blocker as an anti-fibrotic treatment for chronic Hepatitis C was withdrawn from the stud…
-
CLINICAL_TRIALS withdrawal · 2012-03-19Clinical Trial Update: 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C [Phase 3]
A Phase 3 trial evaluating 24- versus 48-week pegylated interferon alfa-2a therapy for genotype 2/3 chronic hepatitis C was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-02-03Clinical Trial Update: Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C [Phase 3]
Phase 3 trial comparing pegylated interferon lambda to pegylated interferon alfa plus ribavirin for hepatitis C was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-01-19Clinical Trial Update: Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients [Phase 4]
A Phase 4 trial comparing maraviroc versus etravirine in combination antiretroviral therapy for drug-experienced HIV patients co-infected wi…
-
CLINICAL_TRIALS withdrawal · 2011-03-15Clinical Trial Update: A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I [Phase 2]
This is a Phase 2 clinical trial update indicating withdrawal of a study evaluating BMS-824393 in combination with peginterferon alfa-2a and…
-
CLINICAL_TRIALS withdrawal · 2009-02-04Clinical Trial Update: Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy
The clinical trial evaluating neurocognitive performance in patients undergoing drug substitution during hepatitis C therapy was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2008-09-29Clinical Trial Update: A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers [Phase 1, Phase 2]
This clinical trial update indicates that the Phase 1/2 study of A-831 in chronic hepatitis C carriers has been terminated.
-
CLINICAL_TRIALS withdrawal · 2007-11-06Clinical Trial Update: Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers [Phase 1]
A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of XTL 2125 in chronic hepatitis C virus infection patients wh…
-
CLINICAL_TRIALS withdrawal · 2007-01-12Clinical Trial Update: Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C [Phase 3]
Phase 3 trial evaluating pentoxifylline and tocopherol for liver fibrosis in chronic hepatitis C was terminated.
-
CLINICAL_TRIALS withdrawal · 2006-07-27Clinical Trial Update: A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects [Phase 2]
A Phase 2 trial comparing Kaletra-based induction/maintenance therapy to a Sustiva-based regimen in previously untreated HIV-1/Hepatitis C c…
-
EMA withdrawal · 2006-06-28EMA Refused: Alpheon (recombinant human interferon alfa-2a) — BioPartners GmbH
The EMA refused approval for Alpheon (recombinant human interferon alfa-2a) from BioPartners GmbH for chronic hepatitis C.
-
EMA withdrawal · 2006-06-01EMA Withdrawn: Infergen (interferon alfacon-1) — Astellas Pharma Europe B.V.
Infergen (interferon alfacon-1) has been withdrawn by Astellas Pharma Europe B.V. for chronic hepatitis C.